Researchers examined 225 children and adults with Lennox-Gastaut syndrome and found that those who received 20 mg/kg and 10 mg/kg of the cannabis compound cannabidiol had a 41.9% and 37.2% median reduction in drop seizure frequency from baseline, respectively, compared with a 17.2% decline among those who took placebo. However, the findings in The New England Journal of Medicine showed that the most common cannabidiol-related adverse effects, such as diarrhea, reduced appetite and somnolence, were more prevalent among those in the higher-dose group.